A.P. Møller - Mærsk A/S
13.7.2026 11:10:54 CEST | Globenewswire | Press release
Transactions in connection with share buy-back program
Transactions in connection with share buy-back program
ANNOUNCEMENT
A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program
On 5 February 2026, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 6.3bn (around USD 1bn) to be executed over a period of 12 months. The first phase of the share buy-back program will run from 9 February 2026 up to 5 August 2026. The shares to be acquired will be limited to a total market value of DKK 3.15 billion (around USD 500m).
The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).
The following transactions have been made under the program in the period 6 July to 10 July 2026:
| Number of A shares | Average purchase price A shares, DKK | Transaction value, A shares, DKK | |
| Accumulated, last announcement | 31,348 | 489,511,440 | |
| 6 July 2026 | 300 | 15,672.9667 | 4,701,890 |
| 7 July 2026 | 300 | 15,714.3667 | 4,714,310 |
| 8 July 2026 | 300 | 16,017.5333 | 4,805,260 |
| 9 July 2026 | 300 | 15,901.7333 | 4,770,520 |
| 10 July 2026 | 300 | 15,540.7000 | 4,662,210 |
| Total 6-10 July | 1,500 | 23,654,190 | |
| Accumulated in the second phase of the program | 32,848 | 513,165,630 | |
| Accumulated under the program | 32,848 | 513,165,630 | |
| Number of B shares | Average purchase price B shares, DKK | Transaction value, B shares, DKK | |
| Accumulated, last announcement (market and the Foundation) | 125,392 | 1,993,639,712 | |
| 6 July 2026 | 1,052 | 16,070.2947 | 16,905,950 |
| 7 July 2026 | 1,052 | 16,085.4278 | 16,921,870 |
| 8 July 2026 | 1,052 | 16,439.9097 | 17,294,785 |
| 9 July 2026 | 1,052 | 16,323.7452 | 17,172,580 |
| 10 July 2026 | 1,052 | 15,881.3498 | 16,707,180 |
| Total 6-10 July | 5,260 | 85,002,365 | |
| Bought from the Foundation* | 740 | 16,160.1454 | 11,958,508 |
| Accumulated in the second phase of the program (market and the Foundation) | 131,392 | 2,090,600,585 | |
| Accumulated under the program (market and the Foundation) | 131,392 | 2,090,600,585 |
*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.
With the transactions stated above, the Company owns a total of 32,848 A shares and 200,439 B shares as treasury shares, corresponding to 1.59% of the share capital.
Details of each transaction are included as appendix.
Copenhagen, 13 July 2026
Contact persons:
Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521
Page 1 of 1
Attachments
- Announcement - Transactions in connection with share buy-back program - week 28 2026
- Daily transactions in connection with share buy-back program - week 28 2026
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Circle8 Group, Inc.13.7.2026 14:00:00 CEST | Press release
Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector
Nykredit Realkredit A/S13.7.2026 13:42:22 CEST | Press release
Fixing of coupon rates - Nykredit Realkredit A/S
Nykredit Realkredit A/S13.7.2026 13:42:22 CEST | Pressemeddelelse
Fastsættelse af kuponrenter - Nykredit Realkredit A/S
Royal UNIBREW A/S13.7.2026 13:28:16 CEST | Press release
Share buy-back program
Veraxa Biotech AG13.7.2026 13:00:00 CEST | Press release
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom